Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Nina N Brahme"'
Autor:
Thomas M Herndon, Cristina Ausin, Nina N Brahme, Sarah J Schrieber, Michelle Luo, Frances C Andrada, Carol Kim, Wanjie Sun, Lingjie Zhou, Stella Grosser, Sarah Yim, M Stacey Ricci
Publikováno v:
PLoS ONE, Vol 18, Iss 10, p e0292231 (2023)
Biosimilars are increasingly available for the treatment of many serious disorders, however some concerns persist about switching a patient to a biosimilar whose condition is stable while on the reference biologic. Randomized controlled studies and e
Externí odkaz:
https://doaj.org/article/0f459bb1654048f39c0ff91ad7b48459
Publikováno v:
Drug Resistance Updates. 30:48-62
Predictive biomarkers for oncology are necessary to accurately identify patients who will benefit from anticancer treatment. Recently approved oncology drugs target discrete molecular aberrations or pathways in tumor cells and consequently are active
Publikováno v:
Biochemistry
Integrins are heterodimeric cell surface adhesion receptors essential for multicellular life. They connect cells to the extracellular environment and transduce chemical and mechanical signals to and from the cell. Intracellular proteins that bind the
Autor:
Srikala Raghavan, David S. Harburger, Madeline Parsons, Rachel M. Stewart, Karl Kemp-O'Brien, David A. Calderwood, Nina N. Brahme
Publikováno v:
Journal of Biological Chemistry. 288:35604-35616
Focal adhesions (FAs), sites of tight adhesion to the extracellular matrix, are composed of clusters of transmembrane integrin adhesion receptors and intracellular proteins that link integrins to the actin cytoskeleton and signaling pathways. Two int
Autor:
Louise E. Bird, Robert J.C. Gilbert, Luke A. Yates, David A. Calderwood, Nina N. Brahme, Ruta Zalyte, Craig N. Lumb, Raymond J. Owens, Luigi De Colibus, Mark S.P. Sansom
Publikováno v:
The Journal of Biological Chemistry
Background: Kindlins are essential co-activators with talin of integrins. Results: Kindlin-1 PH domain is necessary for integrin activation and has low affinity for PtdInsP species partly determined by a salt bridge across its binding pocket. Conclus
Autor:
Nina N. Brahme, David A. Calderwood
Publikováno v:
Current Biology. 22:R692-R694
Integrins are heterodimeric αβ transmembrane receptors that play key roles in cellular physiology and pathology. Accumulating data indicate that the two NPxY motifs in the cytoplasmic domain of the β1 subunit synergistically promote integrin activ
Autor:
Amy L. Stiegler, Nikit Kumar, Titus J. Boggon, Srikala Raghavan, Clotilde Huet-Calderwood, David A. Calderwood, Nina N. Brahme
Publikováno v:
Journal of cell science. 127(Pt 19)
Kindlins are essential FERM-domain-containing focal adhesion (FA) proteins required for proper integrin activation and signaling. Despite the widely accepted importance of each of the three mammalian kindlins in cell adhesion, the molecular basis for
Autor:
Benjamin T. Goult, Clotilde Huet-Calderwood, David A. Calderwood, Nina N. Brahme, Igor L. Barsukov, Mohamed Bouaouina, Neil Bate, David R. Critchley
Publikováno v:
The Journal of biological chemistry. 287(10)
The activation of heterodimeric integrin adhesion receptors from low to high affinity states occurs in response to intracellular signals that act on the short cytoplasmic tails of integrin beta subunits. Binding of the talin FERM (four-point-one, ezr
Autor:
Ziba Razinia, Roberto Buccione, Nina N. Brahme, Massimiliano Baldassarre, David A. Calderwood
Publikováno v:
Journal of Cell Science.
Filamins are an important family of actin-binding proteins that, in addition to bundling actin filaments, link cell-surface adhesion proteins, signaling receptors, and channels to the actin cytoskeleton, and serve as scaffolds for an array of intrace
Autor:
Welch J; US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Silver Spring, Maryland, USA., Ausin C; US Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Therapeutic Biologics and Biosimilars, Silver Spring, Maryland, USA., Brahme N; US Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Therapeutic Biologics and Biosimilars, Silver Spring, Maryland, USA., Lacana E; US Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Therapeutic Biologics and Biosimilars, Silver Spring, Maryland, USA., Ricci S; US Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Therapeutic Biologics and Biosimilars, Silver Spring, Maryland, USA., Schultz-DePalo M; US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Silver Spring, Maryland, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 May; Vol. 113 (5), pp. 1003-1010. Date of Electronic Publication: 2022 Nov 21.